Search

Your search keyword '"Gaal, Luc Van"' showing total 11 results
Start Over Author "Gaal, Luc Van" Publisher american diabetes association
11 results on '"Gaal, Luc Van"'

1. 1836-P: Nonalcoholic Steatohepatitis (NASH) Significantly Contribute to ß-Cell Function Impairment Independently of Glucose Tolerance Status

Author

VONGHIA, LUISA, primary, DIRINCK, EVELINE, additional, CARLI, FABRIZIA, additional, VERRIJKEN, AN, additional, WEYLER, JONAS, additional, MICHIELSEN, PETER, additional, VANWOLLEGHEM, THOMAS, additional, DRIESSEN, ANN, additional, GAAL, LUC VAN, additional, FRANCQUE, SVEN, additional, DE BLOCK, CHRISTOPHE, additional, and GASTALDELLI, AMALIA, additional

Published
2020
Full Text
View/download PDF

3. Depot-specific differences in adipose tissue gene expression in lean and obese subjects

Author

Lefebvre, Anne-Marie, Laville, Martine, Vega, Nathalie, Riou, Jean Paul, Gaal, Luc van, Auwerx, Johan, and Vidal, Hubert

Subjects
Obesity -- Health aspects -- Risk factors -- Genetic aspects, Adipose tissues -- Genetic aspects -- Health aspects, Type 2 diabetes -- Risk factors -- Genetic aspects, Health, Genetic aspects, Risk factors, Health aspects
Abstract

Intra-abdominal and subcutaneous adipose tissue display important metabolic differences that underlie the association of visceral, but not subcutaneous, fat with obesity-related cardiovascular and metabolic problems. Because the molecular mechanisms contributing [...]

Published
1998

5. Improved Cardiovascular and Renal Outcomes in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program Irrespective of Baseline (BL) Body Mass Index (BMI)

Author

BAYS, HAROLD, primary, GAAL, LUC VAN, additional, ARAVIND, S.R., additional, AGGARWAL, NARESH, additional, VIOLANTE, RAFAEL, additional, SLEE, APRIL, additional, SHAW, WAYNE, additional, MAHAFFEY, KENNETH W., additional, ZEEUW, DICK DE, additional, and MATTHEWS, DAVID R., additional

Published
2018
Full Text
View/download PDF

7. High Frequency of Persisting or Increasing Islet-Specific Autoantibody Levels After Diagnosis of Type 1 Diabetes Presenting Before 40 Years of Age

Author

DECOCHEZ, KATELIJN, TITS, JOZEF, COOLENS, JEAN-LUC, GAAL, LUC VAN, KRZENTOWSKI, GEORGES, WINNOCK, FREDERIC, ANCKAERT, ELLEN, WEETS, ILSE, PIPELEERS, DANIEL G., and GORUS, FRANS K.

Subjects
Type 1 diabetes -- Development and progression, Islet cell stimulating antibodies -- Measurement, Health, Development and progression, Measurement
Abstract

THE BELGIAN DIABETES REGISTRY OBJECTIVE -- To study the presence and levels of GAD65 antibodies (GADA), IA-2 antibodies (IA-2-A), and islet cell antibodies (ICA) during the first years after clinical [...]

Published
2000

8. Helicobacter pylori Infection and Autoimmune Gastropathy in Type 1 Diabetes

Author

DE BLOCK, CHRISTOPHE, LEEUW, IVO DE, GAAL, LUC VAN, IEVEN, MARGARETA, BOGERS, JOHANNES, VAN MARCK, ERIC, and PELCKMANS, PAUL

Subjects
Diabetes -- Research, Health
Abstract

Approximately 15-20% of type 1 diabetic patients have gastric parietal cell antibodies (PCA), which can be accompanied by autoimmune atrophic gastritis. Recently, Helicobacter pylori (HP) infection has been implied in [...]

Published
2000

10. Clinically Relevant Weight Loss Achieved with Sibutramine in High-RiskType 2 Diabetic Patients - An Analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.

Author

Gaal, Luc Van, Caterson, Ian, Coutinho, Walmir, Finer, Nick, Maggioni, Aldo, Sharma, Aryam, Torppedersen, Christian, and James, Philip

Subjects
*SIBUTRAMINE, *WEIGHT loss, *PEOPLE with diabetes, *CARDIOVASCULAR diseases, *DISEASE risk factors
Abstract

The article focuses on a study that assesses the effect of sibutramine use on weight loss in type 2 diabetic patients. It states that subjects in this study entered an initial single-blind, 6-week lead-in period with sibutramine and weight management. Diabetics with cardiovascular disease and another risk factor are the eligible patients in the study.

Published
2007

11. Immediate Response of Waist Circumference to Sibutramine in High-Risk Diabetic and Non-Diabetic Patients - An Analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.

Author

Finer, Nick, Caterson, Ian, Coutinho, Walmir, Gaal, Luc Van, Maggioni, Aldo, Sharma, Arya M., Torppedersen, Christian, and James, Philip

Subjects
CLINICAL trials, SIBUTRAMINE, BODY weight, OVERWEIGHT persons, PEOPLE with diabetes, CARDIOVASCULAR diseases, DISEASE risk factors
Abstract

The article presents information on the SCOUT trial that assesses the ability of sibutramine to reduce waist circumference and body weight in obese and overweight patients with and without diabetes at a high risk of a cardiovascular event. A 10 mg of sibutramine with weight management were given to patients. It says that more than 80% of the patients had diabetes and another risk factor.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results